Immunomodulation of cancer: Potential use of selectively replicating agents

Journal of Clinical Investigation

Volumn 105, Issue 9, 2000, Pages 1173-1176

  Agha Mohammadi, Siamak ^a   Lotze, Michael T ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DNA VACCINE; TUMOR VACCINE;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; GENE THERAPY; HUMAN; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR REJECTION;

EID: 0034026546     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI10026     Document Type: Review

References (37)

1. Leroy, P., et al. 1998. Cancer immunotherapy by direct in vivo transfer of immunomodulatory genes. Res. Immunol. 149:681-684.
2. Panelli, M.C., and Marincola, F.M. 1998. Immunotherapy update: from interleukin-2 to antigen-specific therapy. In ASCO educational book. M.C. Perry, editor. American Society of Clinical Oncology. Chicago, Illinois, USA. 467-473.
3. Colombo, M.P., Modesti, A., Parmiani, G., and Forni, G. 1992. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res. 52:4853-4857.
4. Fearon, E.R., et al. 1990. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell. 60:397-403.
5. Viret, C., and Lindemann, A. 1997. Tumor immunotherapy by vaccination with cytokine gene transfected cells. Int. Rev. Immunol. 14:193-212.
6. Golumbek, P.T., et al. 1991. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science. 254:713-716.
7. Lotze, M.T., Grimm, E.A., Mazumder, A., Strausser, J.L., and Rosenberg, S.A. 1981. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res. 1:4420-4425.
8. Peron, J.-M., Shurin, M.R., and Lotze, M.T. 1999. Cytokine gene therapy of cancer. In Gene therapy of cancer. E.C. Lattime and S.L. Gerson, editors. Academic Press. San Diego, California, USA. 359-371.
9. Bubenik, J., et al. 1988. Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumours in nu/nu mice. Immunol. Lett. 19:279-282.
10. Schmidt, W., et al. 1995. Cancer vaccines: the interleukin 2 dosage effect. Proc. Natl. Acad. Sci. USA. 92:4711-4714.
11. Tahara, H., et al. 1995. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J. Immunol. 154:6466-6474.
12. Rosenberg, S.A., et al. 1999. Human gene marker/therapy clinical protocols. Hum. Gene Ther. 10:3067-3123.
13. Haddada, H., Ragot, T., Cordier, L., Duffour, M.T., and Perricaudet, M. 1993. Adenoviral interleukin-2 gene transfer into P815 tumor cells abrogates tumorigenicity and induces antitumoral immunity in mice. Hum. Gene Ther. 4:703-711.
14. Abdel-Wahab, Z., et al. 1997. A phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: monitoring the humoral immune response. Cancer. 80:401-412.
15. Roth, J.A., and Cristiano, R.J. 1997. Gene therapy for cancer what have we done and where are we going? J. Natl. Cancer Inst. 89:21-39.
16. Belli, F., et al. 1997. Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability. Cancer Immunol. Immunother. 44:197-203.
17. Hurford, R.K., Dranoff, G., Mulligan, R.C., and Tepper, R.I. 1995. Gene therapy of metastatic cancer by in vivo retroviral gene targeting. Nat. Genet. 10:430-435.
18. Addison, C.L., et al. 1995. Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc. Natl. Acad. Sci. USA. 92:522-8526.
19. Bausero, M.A., Panoskaltsis-Mortari, A. Blazar, B.R., and Katsanis, E. 1996. Effective immunization against neuroblastoma using double-transduced tumor cells secreting GM-CSF and interreron-gamma. J. Immunother. Emphasis Tumor Immunol. 19:113-124.
20. Ohe, Y., et al. 1993. Combination effect of vaccination with IL2 and IL4 cDNA transfected cells on the induction of a therapeutic immune response against Lewis lung carcinoma cells. Int. J. Cancer. 53:432-437.
21. Wakimoto, H., et al. 1996. Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4. Cancer Res. 56:1828-1833.
22. Nishihara, K., et al. 1995. Increased in vitro and in vivo tumoricidal activity of a macrophage cell line genetically engineered to express IFN-gamma, IL-4, IL-6, or TNF-alpha. Cancer Gene Ther. 2:113-124.
23. Addison, C.L., et al. 1998. Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors. Gene Ther. 5:1400-1409.
24. Oshikawa, K., et al. 1999. Synergistic inhibition of tumor growth in a murine mammary adenocarcinoma model by combinational gene therapy using IL-12, pro-IL-18, and IL-1beta converting enzyme cDNA. Proc. Natl. Acad. Sci. USA. 96:13351-13356.
25. O'Malley, B.W., Jr., et al. 1999. Limitations of adenovirus-mediated interleukin-2 gene therapy for oral cancer. Laryngoscope. 109:389-395.
26. Marr, R.A., Hitt, M., Muller, W.J., Gauldie, J., and Graham, F.L. 1998. Tumour therapy in mice using adenovirus vectors expressing human TNFa. Int. J. Oncol. 12:509-515.
27. Dvorak, H.F., Nagy, A., Dvorak, J.T., and Dvorak, A.M. 1988. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am. J. Pathol. 133:95-109.
28. Heise, C., and Kirn, D.H. 2000. Replication-sensitive adenoviruses as oncolytic agents. J. Clin. Invest. 105:847-851.
29. Kirn, D. 1999. Selectively replicating viruses as therapeutic agents against cancer. In Gene therapy of cancer. E.C. Lattime and S.L. Gerson, editors. Academic Press. San Diego, California, USA. 235-248.
30. Freytag, S.O., Rogulski, K.R., Paielli, D.L., Gilbert, J.D., and Kim, J.H. 1998. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum. Gene Ther. 9:1323-1333.
31. Worgall, S., Wolff, G., Falck-Pedersen, E., and Crystal, R.G. 1997. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum. Gene Ther. 8:37-44.
32. Yang, Y., Ertl, H.C., and Wilson, J.M. 1994. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity. 1:433-442.
33. Juillard, V., et al. 1995. Long-term humoral and cellular immunity induced by a single immunization with replication-detective adenovirus recombinant vector. Eur. J. Immunol. 25:3467-3473.
34. Heise, C.C., Williams, A., Olesch, J., and Kirn, D.H. 1999. Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects. Cancer Gene Ther. 6:499-504.
35. Mirchandani, D., et al. 1995. Heterogeneity in intratumoral distribution of p53 mutations in human prostate cancer. Am. J. Pathol. 147:92-101.
36. Springer, C.J., and Niculescu-Duvaz, I. 2000. Prodrug-activating systems in suicide gene therapy. J. Clin. Invest. 105:1161-1167.
37. Agha-Mohammadi, S., and Lotze, M.T. 2000. Regulatable systems: applications in gene therapy and replicating viruses. J. Clin. Invest. 105:1177-1182.